Table 3 Patients’ characteristics. NR (Not recorded). PS (Performance status)* (Additional file 8 [21]), EGFR (epidermal growth factor receptor), EGFR mutation (epidermal growth factor receptor with a sensitizing mutation to targeted therapy), ALK (anaplastic lymphoma kinase), Kras (K-rat sarcoma), WT (wild type) meaning no sensitizing mutations are found. cCRT (concurrent chemoradiotherapy), sCRT (sequential chemoradiotherapy). RT (radiotherapy). 4 cycles of chemotherapy are usually given. CV (cisplatin and vinorelbine), CarboV (carboplatin and vinorelbine), GCis (gemcitabine and cisplatin), GCarb (gemcitabine and carboplatin), Pemcarbo (pemetrexed and carboplatin), CisN (cisplatin and navelbine). AE (adverse event)
Patient | Age range | PS | Stage | Histology | Treatment |
|---|---|---|---|---|---|
1 | 45-49y | PS1 | IIIA | Squamous cell carcinoma | cCRT (CVx4; 64Gy in 32#) |
2 | 65-69y | PS0 | IIIA | Squamous cell carcinoma | sCRT (GCarb × 4; 64Gy in 32#) |
3 | 70-74y | PS1 | IIIA | Squamous cell carcinoma | cCRT (CV ×1-stopped due to AE; 64Gy in 32#) |
4 | 70-74y | PS1 | IIIA | Squamous cell carcinoma | sCRT (GCis ×4; 55 Gy in 20#) |
5 | 80-84y | PS1 | IIIA | Adenocarcinoma. EGFR WT | sCRT (pemcarbo ×2- stopped due to AE; 64Gy in 32#) |
6 | 55-59y | PS1 | IIIA | Adenocarcinoma EGFR WT | cCRT (CV ×4, 64Gy in 32#) |
7 | 70-74y | PS1 | IIIB | Squamous cell carcinoma | sCRT (GCarbo ×3- stopped due to AE; 55Gy in 20#) |
8 | 65-69y | PS0 | IIIA | Squamous cell carcinoma | cCRT (CVx3; 55gy in 20#) |
9 | 65-69y | NR | IIIA | Squamous cell carcinoma | RT alone: 55gy in 20# |
10 | 55-59y | NR | IIIA | Squamous cell carcinoma | RT alone: 64Gy in 32# |
11 | 65-69y | NR | IIIB | Squamous cell carcinoma | sCRT (GCisx2 switched to GCarbo x 2 due to AE; 64Gy in 32# |
12 | 65-69y | NR | IIIA | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×4, 64Gy in 32#) |
13 | 75-79y | PS1 | IIIA | Adenocarcinoma. EGFR mutation | Gefitinib ×6 followed by 55 in 20# |
14 | 65-69y | PS0 | IIIA | Adenocarcinoma. EGFR and ALK WT | cCRT (CVx1 switched to CarboV ×3 due to AE; 64Gy in 32#) |
15 | 65-69y | PS1 | IIIA | High grade dysplasia at least; no definitive invasive malignancy | cCRT (CV ×4; 64Gy in 32#) |
16 | 55-59y | PS1 | IIIA | Squamous cell carcinoma | cCRT (CV ×2; 64Gy in 32#) |
17 | 70-74y | NR | IIIB | Adenocarcinoma. EGFR and ALK WT | RT alone: 64Gy in 32# |
18 | 75-79y | PS0 | IIIB | Adenocarcinoma. EGFR and ALK WT | cCRT (CisN; 64Gyin 32#) |
19 | 80-84y | PS2 | IIIB | Squamous cell carcinoma | RT alone: 64Gy in 32# |
20 | 50-54y | PS1 | IIIA | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×4; 64Gy in 32#) |
21 | 50-54y | PS0 | IIIA | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×3; 64Gy in 32#) |
22 | 55-59y | PS1 | IIIB | Adenocarcinoma. EGFR and ALK WT | RT alone: 64Gy in 32# |
23 | 70-74y | PS1 | IIIA | Squamous cell carcinoma | RT alone: 55Gy in 20# |
24 | 75-79y | PS1 | IIIA | Adenocarcinoma. EGFR and ALK WT | sCRT (CVx4; 64Gy in 32#) |
25 | 80-84y | PS1 | IIIA | PD carcinoma(no comment on EGFR/ALK) | RT alone: 55Gy in 20# |
26 | 60-64y | PS0 | IIIA | Adenocarcinoma. EGFR and ALK WT | sCRT (CV ×2 switched to CarboV ×2 due to AE; 64Gy in 32#) |
27 | 80-84y | PS0 | IIIA | Squamous cell carcinoma | cCRT (CV ×4; 64Gy in 32#) |
28 | 45-49y | PS1 | IIIB | Squamous cell carcinoma | cCRT (CV ×4; 64Gy in 32#) |
29 | 65-69y | PS1 | IIIA | Squamous cell carcinoma | cCRT (CarboVx3; 64Gy in 32#) |
30 | 45-49y | PS1 | IIIA | Adenocarcinoma-insufficient material for ALK/EGFR testing | sCRT (cispem ×4; 64Gy in 32#) |
31 | 65-69y | PS0 | IIIA | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×4; 64Gy in 32#) |
32 | 60-64y | PS1 | IIIA | Adenocarcinoma. EGFR and ALK WT | sCRT (cispemx2 switched to CV ×2 due to AE; 64Gy in 32#) |
33 | 60-64y | PS1 | IIIB | Squamous cell carcinoma | cCRT (CV ×4; 64Gy in 32#) |
34 | 70-74y | PS1 | IIIB | Squamous cell carcinoma | RT alone: 64Gy in 32# |
35 | 60-64y | PS1 | IIIB | Adenocarcinoma. EGFR and ALK WT, KRAS mutation | cCRT (CV ×4; 64Gy in 32#) |
36 | 45-49y | PS1 | IIIA | NSCLC-not possible to further differentiate tumour type | cCRT (CV ×4; 64Gy in 32#) |
37 | 70-74y | PS2 | IIIA | Squamous cell carcinoma | RT alone: 55Gy in 20# |
38 | 65-69y | PS1 | IIIB | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×4; 64Gy in 32#) |
39 | 55-59y | PS1 | IIIB | Adenocarcinoma. EGFR and ALK WT | cCRT (CV ×6; 64Gy in 32#) |
40 | 80-84y | PS1 | IIIA | Adenocarcinoma | RT alone: 55Gy in 20# |
41 | 75-79y | NR | IIIB | Adenocarcinoma. EGFR and ALK WT | RT alone: 64Gy in 32#; declined chemotherapy |
42 | 60-64y | PS2 | IIIA | Adenocarcinoma. EGFR and ALK WT | RT alone: 55Gy in 20# |
43 | 85-89y | PS1 | IIIA | Squamous cell carcinoma | RT alone: 55Gy in 20# |